The US Market for Therapeutic Apheresis to Reach US$138.9 Million by 2017, According to a New Report by Global Industry Analysts, Inc.

Share Article

GIA announces the release of a comprehensive business report on the US Therapeutic Apheresis market. The US market for Therapeutic Apheresis is forecast to reach US$138.9 million by the year 2017. The market for Therapeutic Apheresis is driven by rapid growth in the photopheresis segment, as well as Erythrocytapheresis and Plateletpheresis gaining wide impetus during the past few years. Efforts towards increasing research for new technology, innovative products, and novel applications is likely to provide the much needed thrust for the growth of Therapeutic Apheresis market in the US.

Therapeutic Apheresis: A US Market Report

Use of Therapeutic Apheresis in the US has increased substantially over the years. The market is presently mature, primarily due to the apprehensions of vendors to infuse funds to further develop new applications. Nevertheless, with new opportunities unfolding for materials, services and apheresis technology devices, investments are likely to flow in. Further, with medical insurance companies customizing their reimbursement policies as per the treated conditions, the high cost of therapeutic apheresis is not likely to hamper market growth. Players are expected to develop technologically improved equipment through strategic collaborations, and are forecast to gain economies of scale, and reduction in the cost of therapy. The potential applications of Therapeutic Apheresis in infants and children remain to be explored, and are likely to offer a potential opportunity for the market expansion.

Although therapeutic apheresis is safe and effective, several users are ignorant of this therapy, and those suffering from chronic diseases go for conventional therapies, presuming it to be the best form of treatment. Even though some patients are aware, they have their own incorrect perceptions that prevent them from adopting apheresis therapy, which eventually restrain market growth. Further, high cost has remained a major market challenge as expensive nature of therapeutic apheresis procedures invariably affects the market shares of various procedures. Nevertheless, reimbursement policies of both government and private insurance companies play a major role in increasing the use of therapeutic apheresis procedures in several diseases.

Photopheresis represents the largest as well as the fastest growing segment in the therapeutic apheresis market, as stated by the new market research report on Therapeutic Apheresis. The segment is further projected to register a Compounded Annual Growth Rate (CAGR) of about 12% over the analysis period. Robust growth of Photopheresis is attributable to its growing demand in off-label indications, such as the prevention of solid organ transplant rejection, and treatment of Graft-Versus-Host Disease (GVHD). Furthermore, growth in the segment is primarily attributed to the clinical potential of photopheresis in autoimmune diseases, such as multiple sclerosis, rheumatoid arthritis, lupus erythematosus, pemphigus, and scleroderma.

Patients develop bleeding disorders from cancer therapy and open-heart surgery. Platelets are an important blood component, particularly in such patients, as they are responsible for blood clotting. Owing to its benefits, platelets are in great demand, however, there is a scarcity of donors with high platelet counts. Single donor platelets are beneficial to blood centers as well as patients. Platelets extracted through apheresis procedure, Plateletpheresis, are the treatment of choice, since the patient is exposed to a single donor. Usage of pathogen reduction technology is another potential opportunity for the development of therapeutic apheresis market. Pathogen Reduction Technology removes disease causing parasites, viruses, and bacteria in transfusion blood.

The US therapeutic apheresis market is oligopolistic, with few key players and several niche players. Pricing pressures and high research and development costs are leading to the market restructuring. Key market alliances and acquisitions are likely to trigger the research and development of technologically advanced apheresis instruments, novel procedures, and more sophisticated therapeutic applications. With aggravating price compression, players are diversifying into blood bank technology and pathogen reduction market. Players profiled in the report include CaridianBCT Inc., Fenwal Inc., Fresenius Medical Care North America, Haemonetics Corp., HemaCare Corp., Therakos Inc., among others.

The research report titled “Therapeutic Apheresis: A US Market Report” announced by Global Industry Analysts Inc., provides a comprehensive review of the Therapeutic Apheresis market, market outlook, key market trends and drivers, market challenges, segmental overview by different procedures, product and technological innovations, recent industry activity, and profiles of select/niche market participants. The report provides annual revenue estimates and projections in the US for the period 2009 through 2017 for the following therapeutic apheresis procedures, which include Plasmapheresis, Erythrocytapheresis, Plateletpheresis, Leukapheresis, Photopheresis, and Lipidpheresis. Also, a six-year (2003-2008) historic analysis is provided for additional perspective.

For more details about this comprehensive market research report, please visit – http://www.strategyr.com/Therapeutic_Apheresis_Market_Report.asp

About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a leading publisher of off-the-shelf market research. Founded in 1987, the company currently employs over 800 people worldwide. Annually, GIA publishes more than 1300 full-scale research reports and analyzes 40,000+ market and technology trends while monitoring more than 126,000 Companies worldwide. Serving over 9500 clients in 27 countries, GIA is recognized today, as one of the world's largest and reputed market research firms.

Follow us on LinkedIn

Global Industry Analysts, Inc.
Telephone: 408-528-9966
Fax: 408-528-9977
Email: press(at)StrategyR(dot)com
Web Site: http://www.StrategyR.com/

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Public Relations
Visit website

Media